chloroquine and derivatives for COVID-19: living meta-analysis of clinical studies

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Endpoint importance	Published MA
efficacy endpoints 00
deaths	0.68 [0.22, 2.08]	< 1	0%	1 study (1/-)	75.2 %	NA	not evaluable	crucial	-
infection (PCR positive symptomatic or not)	0.86 [0.52, 1.42]	< 1	0%	1 study (1/-)	72.2 %	NA	not evaluable	non important	-
safety endpoints 00
serious adverse events	0.89 [0.44, 1.82]	< 1	0%	1 study (1/-)	62.2 %	NA	not evaluable	important	-
adverse events	20.26 [15.67, 26.20]	< 1	0%	1 study (1/-)	0.0 %	NA	not evaluable	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

chloroquine and derivatives - versus standard of care - for COVID-19 prophylaxis (excluding children) pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00